Glucagon-like peptide-1: difference between revisions
Diff·revision 30 → 31·22:39, 23 Nov 2024
Difference between revision 30 and revision 31 of Glucagon-like peptide-1. 6 lines changed; the page grew by 139 bytes.
| Revision 30 — 00:01, 17 Nov 2024 DPP4_Dagmar (talk) ce per MOS 8,088 bytes ±0 | Revision 31 — 22:39, 23 Nov 2024 TalkPageTaro (talk) restructure 8,227 bytes +139 | ||
|---|---|---|---|
| 67 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> | 67 | <ref name="deacon1995">Deacon CF, Johnsen AH, Holst JJ. "Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo." ''Journal of Clinical Endocrinology and Metabolism'' 80(3):952–957 (1995). PMID 7883856.</ref> |
| 68 | 68 | ||
| + | 69 | == See also == | |
| + | 70 | * [[GLP-1 receptor]] | |
| + | 71 | * [[Glucose-dependent insulinotropic polypeptide]] | |
| + | 72 | * [[Incretin effect]] | |
| + | 73 | * [[Dipeptidyl peptidase-4]] | |
| + | 74 | ||
| 69 | {{DEFAULTSORT:Glucagon-like peptide-1}} | 75 | {{DEFAULTSORT:Glucagon-like peptide-1}} |
| 70 | [[Category:Incretin biology]] | 76 | [[Category:Incretin biology]] |